Genkyotex SA, a biopharmaceutical company, develops oral small molecule NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company's lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis a fibrotic orphan disease and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its preclinical stage product candidate is GKT771, a NOX1 inhibitor targeting various pathways in pain processing and inflammation. Genkyotex SA has a license agreement with Serum Institute of India Ltd. for GTL003, an antigen for use in the development of acellular multivalent combination vaccines against a variety of infectious diseases. The company was founded in 2006 and is headquartered in Labège, France.
Visit company website
5 years, 4 months ago
Genkyotex SA is currently in a long term downtrend where the price is trading 0.6% below its 200 day moving average.
From a valuation standpoint, the stock is 30.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 356.7.
Its net income has dropped by 0.0% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 45.3% to $-1M since the same quarter in the previous year.
Based on the above factors, Genkyotex SA gets an overall score of 0/5.